Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panitumumab + Gemcitabine in Advanced Pancreatic Cancer
NCT00613730Phase 2Terminated
- Sponsor
- Amgen
- Start
- Jan 2007
- Primary completion
- Apr 2009
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
01
Overview
A Phase 2 trial of panitumumab in pancreatic adenocarcinoma (PDAC), sponsored by Amgen. Started Jan 2007; status: terminated.
02
Drugs
panitumumab
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT00613730.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00613730.